These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16901414)

  • 1. The CARDS trial: diabetic patients dealt a winning hand.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2006 Sep; 8(5):429-32. PubMed ID: 16901414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
    März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C;
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 8. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
    Croom KF; Plosker GL
    Drugs; 2005; 65(1):137-52. PubMed ID: 15610062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
    Brandle M; Davidson MB; Schriger DL; Lorber B; Herman WH
    Diabetes Care; 2003 Jun; 26(6):1796-801. PubMed ID: 12766112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins for patients with type 2 diabetes.
    Pimpinella G; Bertini Malgarini R; Martini N
    Lancet; 2004 Nov 27-Dec 3; 364(9449):1933; author reply 1933. PubMed ID: 15566999
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins for patients with type 2 diabetes.
    Auer J; Berent R; Weber T; Eber B
    Lancet; 2004 Nov 27-Dec 3; 364(9449):1933-4. PubMed ID: 15566997
    [No Abstract]   [Full Text] [Related]  

  • 13. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
    Lafuma A; Colin X; Solesse A
    Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
    Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
    Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
    Durazzo AE; Machado FS; Ikeoka DT; De Bernoche C; Monachini MC; Puech-Leão P; Caramelli B
    J Vasc Surg; 2004 May; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
    Bybee KA; Lee JH; O'Keefe JH
    Curr Med Res Opin; 2008 Apr; 24(4):1217-29. PubMed ID: 18358084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.